Improvac

RSS

gonadotropin-releasing-factor-analogue-protein conjugate

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Improvac.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Improvac.

For practical information about using Improvac, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 05/11/2018

Authorisation details

Product details
Name
Improvac
Agency product number
EMEA/V/C/000136
Active substance
synthetic peptide analogue of gonadotropin-releasing factor conjugated to dipthheria toxoid
International non-proprietary name (INN) or common name
gonadotropin-releasing-factor-analogue-protein conjugate
Species
Pigs (Male)
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI09AX
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
19
Date of issue of marketing authorisation valid throughout the European Union
10/05/2009
Contact address
Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

25/10/2018 Improvac - EMEA/V/C/000136 - IG/0976

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for suidae

Therapeutic indication

Induction of antibodies against gonadotrophin-releasing factor (GnRF) to produce a temporary immunological suppression of testicular function. For use as an alternative to physical castration for the reduction of boar taint caused by the key boar-taint compound androstenone, in entire male pigs following the onset of puberty. Another key contributor to boar taint, skatole, may also be reduced as an indirect effect. Aggressive and sexual (mounting) behaviours are also reduced.

Assessment history

How useful was this page?

Add your rating